Steven Cohen Adaptimmune Therapeutics PLC Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $85,785 - $147,060	64,500 Added 11.07%	647,008 $1.1 Million
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $29,929 - $70,238	17,300 Added 3.06%	582,508 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $1.71 Million - $2.78 Million	488,908 Added 640.77%	565,208 $2.12 Million
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $6.82 Million - $12.6 Million	-1,982,792 Reduced 96.29%	76,300 $394,000
Q2 2021 Aug 16, 2021	BUY	$3.86 - $5.78 $312,111 - $467,359	80,858 Added 4.09%	2,059,092 $8.77 Million
Q1 2021 May 17, 2021	BUY	$4.9 - $6.83 $1.12 Million - $1.56 Million	228,234 Added 13.04%	1,978,234 $10.5 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $7 Million - $16.1 Million	1,750,000 New	1,750,000 $9.43 Million
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $1.13 Million - $4.25 Million	-300,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $2.48 Million - $4.07 Million	300,000 New	300,000 $4.07 Million
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $687,990 - $1.12 Million	-96,900 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $647,292 - $846,906	96,900	96,900 $647,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.